Cargando…
Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go?
Placebo effects are well established in healthy participants experiencing experimental or acute pain. Yet, little is known about the mechanisms of placebo analgesia effects in patients with chronic pain and even less is known in patients suffering from central nervous system (CNS) diseases where pai...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749922/ https://www.ncbi.nlm.nih.gov/pubmed/31583343 http://dx.doi.org/10.1097/PR9.0000000000000717 |
_version_ | 1783452374714548224 |
---|---|
author | Matthiesen, Susan Tomczak Lunde, Sigrid Juhl Wohlert Kjær, Sophie Carlino, Elisa Vase, Lene |
author_facet | Matthiesen, Susan Tomczak Lunde, Sigrid Juhl Wohlert Kjær, Sophie Carlino, Elisa Vase, Lene |
author_sort | Matthiesen, Susan Tomczak |
collection | PubMed |
description | Placebo effects are well established in healthy participants experiencing experimental or acute pain. Yet, little is known about the mechanisms of placebo analgesia effects in patients with chronic pain and even less is known in patients suffering from central nervous system (CNS) diseases where pain is prevalent, difficult to manage, and often undertreated. This article briefly reviews the current knowledge of placebo analgesia effects in healthy participants with the aim of discussing how the mechanisms in placebo analgesia differ between healthy participants and patients. The focus will be on placebo analgesia effects in chronic pain conditions as well as in 2 CNS diseases: Alzheimer disease and Parkinson disease. Finally, strengths and weaknesses of the current knowledge will be discussed and it will be demonstrated how insights from the placebo literature may point to new ways of improving treatments among patients experiencing pain in relation to CNS diseases. |
format | Online Article Text |
id | pubmed-6749922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-67499222019-10-03 Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? Matthiesen, Susan Tomczak Lunde, Sigrid Juhl Wohlert Kjær, Sophie Carlino, Elisa Vase, Lene Pain Rep Placebo and Pain Research: From Bench-to-Bedside and Beyond Placebo effects are well established in healthy participants experiencing experimental or acute pain. Yet, little is known about the mechanisms of placebo analgesia effects in patients with chronic pain and even less is known in patients suffering from central nervous system (CNS) diseases where pain is prevalent, difficult to manage, and often undertreated. This article briefly reviews the current knowledge of placebo analgesia effects in healthy participants with the aim of discussing how the mechanisms in placebo analgesia differ between healthy participants and patients. The focus will be on placebo analgesia effects in chronic pain conditions as well as in 2 CNS diseases: Alzheimer disease and Parkinson disease. Finally, strengths and weaknesses of the current knowledge will be discussed and it will be demonstrated how insights from the placebo literature may point to new ways of improving treatments among patients experiencing pain in relation to CNS diseases. Wolters Kluwer 2019-06-07 /pmc/articles/PMC6749922/ /pubmed/31583343 http://dx.doi.org/10.1097/PR9.0000000000000717 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Placebo and Pain Research: From Bench-to-Bedside and Beyond Matthiesen, Susan Tomczak Lunde, Sigrid Juhl Wohlert Kjær, Sophie Carlino, Elisa Vase, Lene Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title_full | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title_fullStr | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title_full_unstemmed | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title_short | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
title_sort | placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
topic | Placebo and Pain Research: From Bench-to-Bedside and Beyond |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749922/ https://www.ncbi.nlm.nih.gov/pubmed/31583343 http://dx.doi.org/10.1097/PR9.0000000000000717 |
work_keys_str_mv | AT matthiesensusantomczak placeboanalgesiaeffectsacrosscentralnervoussystemdiseaseswhatdoweknowandwheredoweneedtogo AT lundesigridjuhl placeboanalgesiaeffectsacrosscentralnervoussystemdiseaseswhatdoweknowandwheredoweneedtogo AT wohlertkjærsophie placeboanalgesiaeffectsacrosscentralnervoussystemdiseaseswhatdoweknowandwheredoweneedtogo AT carlinoelisa placeboanalgesiaeffectsacrosscentralnervoussystemdiseaseswhatdoweknowandwheredoweneedtogo AT vaselene placeboanalgesiaeffectsacrosscentralnervoussystemdiseaseswhatdoweknowandwheredoweneedtogo |